Drug shows promise for kids with Arthritis-Related eye disease

NCT ID NCT01385826

Completed Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested the drug adalimumab against a placebo in 34 children with juvenile arthritis and active eye inflammation (uveitis) that wasn't controlled by steroid drops or methotrexate. The goal was to see if adalimumab could reduce eye inflammation after two months. After that, all participants could receive adalimumab for up to a year to track safety and long-term effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: adalimumab (a drug that blocks inflammation)
What this could lead to: If it works, this could provide a treatment option for children with arthritis-related eye inflammation that hasn't responded to standard therapies.
What could go wrong: This is a small, early-phase trial with only 34 participants. The results may not apply to all children, and long-term safety and effectiveness are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates